JP7835392B2 - 単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体 - Google Patents

単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体

Info

Publication number
JP7835392B2
JP7835392B2 JP2021556422A JP2021556422A JP7835392B2 JP 7835392 B2 JP7835392 B2 JP 7835392B2 JP 2021556422 A JP2021556422 A JP 2021556422A JP 2021556422 A JP2021556422 A JP 2021556422A JP 7835392 B2 JP7835392 B2 JP 7835392B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
nucleic acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525535A5 (enExample
JP2022525535A (ja
Inventor
シー ヘロルド，ベッツィ
ケルソー，ガーネット
雅征 倉岡
バーン，クレア
アール，ジュニア ジェイコブズ，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of JP2022525535A publication Critical patent/JP2022525535A/ja
Publication of JP2022525535A5 publication Critical patent/JP2022525535A5/ja
Application granted granted Critical
Publication of JP7835392B2 publication Critical patent/JP7835392B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021556422A 2019-03-19 2020-03-19 単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体 Active JP7835392B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820495P 2019-03-19 2019-03-19
US62/820,495 2019-03-19
PCT/US2020/023600 WO2020191181A1 (en) 2019-03-19 2020-03-19 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Publications (3)

Publication Number Publication Date
JP2022525535A JP2022525535A (ja) 2022-05-17
JP2022525535A5 JP2022525535A5 (enExample) 2023-03-07
JP7835392B2 true JP7835392B2 (ja) 2026-03-25

Family

ID=70285944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556422A Active JP7835392B2 (ja) 2019-03-19 2020-03-19 単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体

Country Status (9)

Country Link
US (1) US12459987B2 (enExample)
EP (1) EP3941524A1 (enExample)
JP (1) JP7835392B2 (enExample)
KR (1) KR20210141948A (enExample)
CN (2) CN113661176B (enExample)
AU (1) AU2020242042A1 (enExample)
CA (1) CA3133862A1 (enExample)
IL (1) IL286415A (enExample)
WO (1) WO2020191181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805579B (zh) * 2022-06-08 2023-06-06 郑州大学 一种抗人ace2蛋白单克隆抗体、核酸分子及应用
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
CN119751660B (zh) * 2024-12-02 2026-04-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种猫麻疹病毒特异性单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506403A (ja) 2009-10-01 2013-02-28 ユニバーシタット ダイズバーグ−エッセン 抗ｈｓｖ抗体
JP2017520572A (ja) 2014-06-26 2017-07-27 ハイデルべルク イミュノセラピューティクス ゲーエムベーハー 抗ｈｓｖ抗体の外用適用
WO2019044926A1 (ja) 2017-08-30 2019-03-07 Ｋｍバイオロジクス株式会社 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU1866895A (en) 1994-01-04 1995-08-01 Scripps Research Institute, The Human monoclonal antibodies to herpes simplex virus and methods therefor
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP2020504105A (ja) 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506403A (ja) 2009-10-01 2013-02-28 ユニバーシタット ダイズバーグ−エッセン 抗ｈｓｖ抗体
JP2017520572A (ja) 2014-06-26 2017-07-27 ハイデルべルク イミュノセラピューティクス ゲーエムベーハー 抗ｈｓｖ抗体の外用適用
WO2019044926A1 (ja) 2017-08-30 2019-03-07 Ｋｍバイオロジクス株式会社 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Med Microbiol Immunol，2010年10月08日，vol. 200, no. 2，pp. 85-97

Also Published As

Publication number Publication date
WO2020191181A9 (en) 2020-12-10
US12459987B2 (en) 2025-11-04
CN113661176A (zh) 2021-11-16
KR20210141948A (ko) 2021-11-23
AU2020242042A1 (en) 2021-09-16
IL286415A (en) 2021-10-31
CA3133862A1 (en) 2020-09-24
CN113661176B (zh) 2025-02-18
JP2022525535A (ja) 2022-05-17
CN119899260A (zh) 2025-04-29
EP3941524A1 (en) 2022-01-26
WO2020191181A1 (en) 2020-09-24
US20220162291A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US8124092B2 (en) Antibodies against H5N1 strains of influenza A virus
JP6676521B2 (ja) 二重特異性分子、薬学的組成物及びそれらの使用
KR102866162B1 (ko) 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
JP7793679B2 (ja) ヒトＴｉｍ－３に対するモノクローナル抗体
EP2308895A1 (en) Anti-HSV antibody
CN104603149B (zh) 与预防和治疗狂犬病感染相关的组合物和方法
JP2022514940A (ja) Ｂ型肝炎ウイルスを中和する抗体およびその使用
KR102656738B1 (ko) 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체 및 이의 사용 방법
US20240262894A1 (en) Antibody against respiratory syncytial virus and use thereof
MX2010009885A (es) Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
US12459987B2 (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2022051223A1 (en) Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
EP2879706B1 (en) Novel anti-plasmodium parasite antibodies
CN107074964A (zh) 抗丙型肝炎抗体及其抗原结合片段
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
CN113583116B (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
IL282135B2 (en) Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc
CN114761428B (zh) 抗血凝素抗体及其使用方法
US20250127885A1 (en) Engineered fc domains and engineered hcmv viral fc receptors
WO2024255841A1 (zh) 乙肝病毒表面抗体及其应用
CN117736314A (zh) 针对SARS-CoV-2和其变异株的中和抗体及其用途
HK40043135B (zh) 针对人tim-3的单克隆抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260304

R150 Certificate of patent or registration of utility model

Ref document number: 7835392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150